Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Principal Financial Group Inc Common Stock (PFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Principal Financial Group Inc Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Principal Financial Group Inc Common Stock trades at $106.98 (market cap $23.04B). The key difference: Principal Financial Group Inc Common Stock is far larger — about 2.6× Kymera Therapeutics Inc. Common Stock's market cap, and Principal Financial Group Inc Common Stock pays a 3.12% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Principal Financial Group Inc Common Stock for 6 Days on average.
| KYMR | PFG | |
|---|---|---|
Market Cap | $8.87B | $23.04B |
Volume | 779,107 | 1,066,568 |
Sector | Health | Financials |
52-Week High | $127.31 | $118.51 |
52-Week Low | $55.80 | $78.39 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $22.12B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Principal Financial Group (PFG) trades at $107.64, down 0.19% with a bearish technical outlook. The stock shows mixed fundamentals with recent earnings beats but faces valuation concerns at a P/E of 15.33. Recent acquisition of Beam Benefits aims to expand digital capabilities in specialty benefits, while analyst sentiment remains cautious with a 'Hold' consensus rating and $108.33 price target.
PFG presents a balanced risk-reward profile with steady revenue growth and improving profit margins, but faces headwinds from technical weakness and mixed analyst sentiment. The Beam Benefits acquisition provides growth potential in the SMB market, though execution risks and competitive pressures in the multiline insurance sector warrant monitoring for investors seeking exposure to financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Principal Financial Group Inc Common Stock
Principal Financial Group provides retirement, insurance, and asset management services. It serves individuals, employers, and institutional clients.
Read more on PFG →
